摘要
Purpose . To investigate the effects of a combined herbal medicine Miodesin™ on the inflammatory response of key cells involved in the acute and chronic inflammatory processes as well as the possible epigenetic involvement. Methods . After the establishment of the IC 50 dose, the chondrocyte, keratinocyte, and macrophage cell lines were pretreated for 2 hours with Miodesin™ (200 μ g/mL) and stimulated with LPS (1 μ g/mL) for 24 hours. The supernatant was used to measure the levels of cytokines (IL-1 β , IL-6, IL-8, and TNF- α ) and chemokines (CCL2, CCL3, and CCL5), and the cells were used to extract the mRNA for the transcription factor (NF- κβ ), inflammatory enzymes (COX-1, COX-2, PLA2, and iNOS), and chemokines (CCL2, CCL3, and CCL5). Results . Miodesin™ inhibited the release of LPS-induced cytokines (IL-1 β , IL-6, IL-8, and TNF- α ; p<0.01) and chemokines (CCL2, CCL3, and CCL5; p<0.01) and the expression of the transcription factor (NF- κ β ; p<0.01), inflammatory enzymes (COX-1, COX-2, PLA2, iNOS; p<0.01), and chemokines (CCL2, CCL3, and CCL5; p<0.01). In addition, the evaluation of epigenetic mechanism revealed that Miodesin™ did not induce changes in DNA methylation, assuring the genetic safeness of the compound in terms of the inflammatory response. Conclusions . Miodesin™ presents anti-inflammatory properties, inhibiting hyperactivation of chondrocytes, keratinocytes, and macrophages, involving epigenetics in such effects.